It adding the value of the combinations of CSF markers including t-tau, Aβ1–42 and p-tau [40] that been confirmed in large multi-center studies—namely, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study [41] and the Development of Screening Guidelines and Criteria for Predementia Alzheimer’s Disease (DESCRIPA) study [42]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.